Gilead’s HIV Treatments Could Face Headwinds. Why the Stock Will Still Rise.
In This Article:
Gilead Sciences stock has room to climb, and investors shouldn’t overlook the company’s impressive record in navigating HIV policy, Citi Research says. Analysts led by Geoff Meacham reiterated a Buy rating on the shares with a $125 price target in a note Wednesday. With Gilead up 1.2% to $109.23 on Wednesday, the price target suggests potential upside of 14%.
Terms and Privacy Policy